- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05872698
Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of Oesophageal Varices Trial. (BOPPP)
Beta-blockers Or Placebo for Primary Prophylaxis of Oesophageal Varices (BOPPP Trial). A Blinded, UK Multi-centre, Clinical Effectiveness and Cost-effectiveness Randomised Controlled Trial.
Study Overview
Status
Intervention / Treatment
Detailed Description
Cirrhosis or liver scarring is an important problem in healthcare in the United Kingdom. 60,000 patients are living with this disease and about 11,000 people every year will die because of it. There are several ways in which patients with this severe form of liver disease become unwell or die and bleeding from the oesophagus or stomach is one. Cirrhosis causes pressure changes inside the abdomen and swelling of veins in the oesophagus (called "varices") which can bleed catastrophically.
We know that when varices are large we need to treat them with medication called beta-blockers to reduce the pressure in the varices. If the varices are small, we are not sure if we need to treat with beta-blockers and this study aims to address this uncertainty. Patients who are recruited to the study with small varices will be randomised to either beta-blockers or a placebo. We will observe them closely for 3 years for bleeding from their varices or other complications of cirrhosis or side effects of taking medication. This is the amount of time needed to observe for bleeding when the varices are small. We will review the patients every 6 months including assessing the varices by a camera test called an endoscopy at the beginning and each year until the study is finished.
During the study patients will be involved with the conduct and management of the research, and we will feedback to recruited patients the results at the end. We will assess the barriers and facilitators of doctors in primary care - such as General Practitioners - in adjusting the dose of the tablets to optimise treatment effects, and assess patients' views on taking part in the trial, and whether the side effects justify the potential benefits of reducing the risk of bleeding. We estimate this risk could be reduced from 20% of patients having significant bleeding to 10% over 3 years.
We will measure the impact of beta-blockers on the overall costs to the NHS of caring for people with cirrhosis during the trial. We will then assess the impact of treatment on both mortality and quality of life using a combined measure, the Quality Adjusted Life-Year (QALY). We will use a mathematical prediction model to estimate the impact of treatment on costs, mortality and quality of life over a patient's lifetime. We will assess whether any increased costs are justified by better outcomes for patients and represent good value for money for the NHS budget.
Finally, we will publish the results of the study in the medical literature and discuss the findings at medical conferences, patient groups and with charities involved in helping patients with cirrhosis such as the British Liver Trust.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Ruhama Uddin
- Phone Number: 0203 299 7142
- Email: kch-tr.boppptrial@nhs.net
Study Contact Backup
- Name: Vishal Patel
- Email: vishal.patel@nhs.net
Study Locations
-
-
-
London, United Kingdom, SE5 9RS
- Recruiting
- King's College Hospital
-
Contact:
- Mark McPhail
- Email: mark.mcphail@kcl.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 18 years and over
- Cirrhosis and portal hypertension,
- Small oesophageal varices diagnosed within the last 6 months, defined as ≤5 mm in diameter or varices which completely disappear on moderate insufflation at gastroscopy.
- Not received a beta-blocker in the last week
- Capacity to provide informed consent
Exclusion Criteria:
- Non-cirrhotic portal hypertension
- Medium/large oesophageal varices (current or history [decreasing in size without curative therapy]), defined as >5 mm in diameter
- Gastric (IGV and GOV2), duodenal, rectal varices with or without evidence of recent bleeding.
- Previous variceal haemorrhage
- Previous band ligation or glue injection of oesophageal and/or gastric varices
- Red signs accompanying varices at endoscopy
- Known intolerance to beta blockers
- Contraindications to beta blocker use
- Unable to provide informed consent
- Child Pugh C cirrhosis
- Already receiving a beta-blocker for another reason that cannot be discontinued
- Graft cirrhosis post liver transplantation
- Evidence of active malignancy without curative therapy planned
- Pregnant or lactating women
- Women of child bearing potential not willing to use adequate contraception during the period of IMP dosing
- Patients who have been on a CTIMP within the previous 3 months
- Clinical symptoms consistent with COVID-19
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Carvedilol
Oral Carvedilol 6.25 mg to 12.5 mg OD/ or 6.25mg BD (maximum dose 12.5mg)
|
Carvedilol, sold under the brand name Coreg among others, is a medication used to treat high blood pressure, congestive heart failure, and left ventricular dysfunction in people who are otherwise stable.
For high blood pressure, it is generally a second-line treatment.
It is taken by mouth.
|
Placebo Comparator: Placebo
Oral tablet (1 or 2 tablets)
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Variceal Haemorrhage
Time Frame: 3 years from recruitment
|
3 years from recruitment
|
Collaborators and Investigators
Publications and helpful links
Helpful Links
- Using a theory-informed approach to explore patient and staff perspectives on factors that influence clinical trial recruitment for patients with cirrhosis and small oesophageal varices
- General practitioner perspectives on factors that influence implementation of secondary care-initiated treatment in primary care: Exploring implementation beyond the context of a clinical trial
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Gastrointestinal Diseases
- Liver Diseases
- Fibrosis
- Esophageal Diseases
- Hemorrhage
- Liver Cirrhosis
- Esophageal and Gastric Varices
- Hypertension, Portal
- Varicose Veins
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Protective Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Antioxidants
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Carvedilol
Other Study ID Numbers
- 255446
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Portal Hypertension
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingIntrahepatic Non Cirrhotic Portal HypertensionFrance
-
Centro Hospitalar De São João, E.P.E.CompletedClinically Significant Portal HypertensionPortugal
-
University Hospital, ToursCompletedCirrhotic Portal HypertensionFrance
-
Icahn School of Medicine at Mount SinaiNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedPortal Hypertension | Clinically Significant Portal HypertensionUnited States
-
University Hospital, GhentCompletedEvaluation of Efficacy and Safety of Somatostatin Used as Inflow Modulator in Liver Transplantation.Liver Transplant With Clinically Significant Portal HypertensionBelgium
-
Ain Shams UniversityCompleted
-
Universidade Federal do Rio de JaneiroNot yet recruitingPortal Hypertension | Idiopathic Non-Cirrhotic Portal Hypertension | Non-Cirrhotic Portal Hypertension | Vascular Disorder of Liver | Non-Cirrhotic Portal Fibrosis | Regenerative Nodular Hyperplasia | Incomplete Septal Cirrhosis | Obliterative Portal Venopathy | Hepatoportal Sclerosis | Idiopathic Portal...Brazil
-
Assiut UniversityUnknownPredicting Liver Cell Failure & Portal Hypertension in LCEgypt
-
University Hospital, BonnCompleted
-
Tanta UniversityCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States